Scott Rocklage, Ph.D. is a managing partner at 5AM Ventures Management located in Boston, MA. Founded in 2004, the firm specifically invests in next generation life science companies. 5AM Ventures Management has invested in over fifty-four companies to date. The life science companies that they invest in specialize in drug delivery technologies, the discovery and development of therapeutics and research instruments. Dr. Scott Rocklage served as a member of the Board of Directors and the CEO of Cubist Pharmaceuticals. He also served as the president and CEO of Nycomed Salutar and worked in a couple of positions in the Research and Development department for the companies, Salutar and Catalytica. While working for Nycomed Salutar, Dr. Scott Rocklage was the initiator for designing and putting to action a few research and development programs that created drug products in human clinical trials. He was a former Board Chairman of the company Relypsa and Novira, that was recently bought by Johnson and Johnson. Learn more: http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY
For over three decades, Dr. Rocklage has maintained his trust and leadership in the healthcare management field. He graduated with a Bachelor of Science degree in Chemistry from the University of California, Berkeley. He also graduated with a Ph.D. in Chemistry from the Massachusetts Institute of Technology. While attending MIT, Scott would conduct his research and studies inside the lab of Nobel Prize winner, Richard Schrock. Scott Rocklage has earned approval from the FDA for three new US drug applications, the Omniscan, Cubicin and Teslascan. He has invented over thirty US patents and has more than a hundred peer-reviewed publications.